carelizumab + irinotecan + apatinib

This is a combination regimen consisting of three agents: - **Carelizumab (camrelizumab)** is a humanized IgG4 monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor on T cells, acting as an immune checkpoint inhibitor. By blocking PD-1, it prevents interaction with its ligands PD-L1 and PD-L2, thereby restoring T-cell activity against tumor cells and enhancing anti-tumor immunity. - **Irinotecan** is a small molecule chemotherapeutic agent that inhibits topoisomerase I, leading to DNA damage and apoptosis in rapidly dividing cancer cells. - **Apatinib** is a small molecule tyrosine kinase inhibitor that selectively inhibits vascular endothelial growth factor receptor 2 (VEGFR2), thereby blocking angiogenesis required for tumor growth. The combination leverages immunotherapy (carelizumab), cytotoxic chemotherapy (irinotecan), and targeted antiangiogenic therapy (apatinib) to exert synergistic antitumor effects. This approach aims to enhance efficacy by attacking cancer through multiple mechanisms—immune activation, direct cytotoxicity, and inhibition of blood vessel formation[1].

Other names

carelizumab + irinotecan + apatinib